Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 2
Treatment-assignment count: 0
Stratification count: 0
Low Public Signal
KRAS G12C
gastric cancer · Therapy Not Normalized
KRAS G12C is flagged as low public signal because public trials show inclusion required evidence in 2 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: dMMR | BRAF V600E | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04117958 | https://clinicaltrials.gov/study/NCT07001592